About SpringWorks Therapeutics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Stamford, Connecticut
- Founded
- 2017
- Company type
- Public Company
SpringWorks Therapeutics, a healthcare company of Merck KGaA, Darmstadt, Germany, is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with rare tumors.
We developed and are commercializing the first and only FDA and EC approved medicine for adults with desmoid tumors and the first and only FDA and EC approved medicine for both adults and children with neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN).
At SpringWorks, we are committed to finding answers people with rare tumors need. We thrive in an atmosphere of passion and tenacity, fueled by the excitement of the possibilities science may unlock and driven to work with urgency because of the importance of our work. We value authenticity because diverse backgrounds, cultures, styles and abilities can only help us find the answers that people with rare tumors are looking for.
Company locations
100 Washington Blvd, Stamford, Connecticut 06902, US
212 W Main St, Durham, North Carolina 27713, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
Business areas
- Biopharma
- Biotechnology
- Therapeutics
On LinkedIn
- Followers
- 30,464
- People linked to this company
- 341
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
1,015,500,000 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.